- Home
- DTSS vs BIVI Comparison
DTSS vs BIVI Comparison
Compare DTSS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BIVI
- Stock Information
- Founded
- DTSS 2014
- BIVI 2013
- Country
- DTSS China
- BIVI United States
- Employees
- DTSS N/A
- BIVI N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- BIVI Health Care
- Exchange
- DTSS Nasdaq
- BIVI Nasdaq
- Market Cap
- DTSS 17.6M
- BIVI 14.2M
- IPO Year
- DTSS N/A
- BIVI N/A
- Fundamental
- Price
- DTSS $1.95
- BIVI $1.86
- Analyst Decision
- DTSS
- BIVI
- Analyst Count
- DTSS 0
- BIVI 0
- Target Price
- DTSS N/A
- BIVI N/A
- AVG Volume (30 Days)
- DTSS 39.1K
- BIVI 164.7K
- Earning Date
- DTSS 11-12-2025
- BIVI 11-12-2025
- Dividend Yield
- DTSS N/A
- BIVI N/A
- EPS Growth
- DTSS N/A
- BIVI N/A
- EPS
- DTSS N/A
- BIVI N/A
- Revenue
- DTSS $71,616,820.00
- BIVI N/A
- Revenue This Year
- DTSS N/A
- BIVI N/A
- Revenue Next Year
- DTSS N/A
- BIVI N/A
- P/E Ratio
- DTSS N/A
- BIVI N/A
- Revenue Growth
- DTSS 198.70
- BIVI N/A
- 52 Week Low
- DTSS $1.63
- BIVI $1.42
- 52 Week High
- DTSS $3.10
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- DTSS 46.29
- BIVI 44.63
- Support Level
- DTSS $1.88
- BIVI $1.83
- Resistance Level
- DTSS $1.98
- BIVI $1.94
- Average True Range (ATR)
- DTSS 0.08
- BIVI 0.12
- MACD
- DTSS -0.00
- BIVI 0.01
- Stochastic Oscillator
- DTSS 57.14
- BIVI 19.00
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.